Last reviewed 2026-04-20 · How we verify

Citomix (INTERFERON)

Citomix (interferon) is a lymphocyte growth factor developed by Bayer Healthcare Pharmaceuticals. It is a small molecule drug that was approved by the FDA in 2015 for the treatment of seasonal colds. As a lymphocyte growth factor, Citomix works by stimulating the growth and activity of immune cells, helping to fight off infections. The commercial status of Citomix is patented, and it is currently owned by Bayer Healthcare Pharmaceuticals. Key safety considerations include potential side effects such as flu-like symptoms and injection site reactions.

At a glance

Approved indications

• Seasonal colds

Common side effects

• Fever
• Headache
• Rash
• Chills
• Injection site erythema
• Injection site tenderness
• Fatigue
• Diarrhea
• Myalgia

Serious adverse events

• Pancreatitis with fatal outcome
• Acute myocardial infarction
• Cardiac failure
• Acute renal failure
• Pulmonary embolism
• Stevens-Johnson syndrome
• Convulsion/seizure
• Interstitial pneumonitis
• Granulomatous colitis
• Gastrointestinal bleeding

Key clinical trials

• A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] (PHASE3)
• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer (PHASE3)
• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (PHASE3)
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
• Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1,PHASE2)
• A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies (PHASE3)
• Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2,PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.